Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1990 May;31(3):151–156. doi: 10.1007/BF01744729

Comparison of T suppressor factors from tumour-bearing mice and mice immunized with a monoclonal anti-idiotypic antibody

Judith M Greer 1, William J Halliday 1,✉
PMCID: PMC11038534  PMID: 2110863

Abstract

Certain dosage schedules of a monoclonal antiidiotypic antibody (related to a murine bladder carcinoma) were found to induce suppressor factor production by syngeneic mice. This suppressor factor resembled the factor from tumour-bearing mice with respect to idiotype specificity, possession of molecular markers (reactive with anti-IJ and B16G antibodies) and production by Lyt2+IJ+ T cells in spleen cell cultures. The two factors differed with respect to Igh restriction in an in vitro assay (leucocyte adherence inhibition) and ability to suppress the induction of delayed-type hypersensitivity to tumour antigen.

Keywords: Molecular Marker, Spleen Cell, Factor Production, Tumour Antigen, Dosage Schedule

References

  • 1.Deal H, Steele JK, Stammers AT, Singhai R, Levy JG. Preadministration of a T-suppressor factor enhances tumor immunity in DBA/2 mice. Cancer Immunol Immunother. 1989;28:193. doi: 10.1007/BF00204988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Drebin JA, Waltenbaugh C, Schatten S, Benacerraf B, Greene MI. Inhibition of tumor growth by monoclonal anti I-J antibodies. J Immunol. 1983;130:506. [PubMed] [Google Scholar]
  • 3.Greene MI, Fujimoto S, Sehon AH. Regulation of the immune response to tumor antigens. III. Characterization of thymic suppressor factor(s) produced by tumor-bearing hosts. J Immunol. 1977;119:757. [PubMed] [Google Scholar]
  • 4.Greer JM, Halliday WJ. Auto-anti-idiotypic antibodies in mice hyperimmunized with a chemically induced bladder carcinoma. Immunol Cell Biol. 1988;66:167. doi: 10.1038/icb.1988.21. [DOI] [PubMed] [Google Scholar]
  • 5.Halliday WJ, Miller S. Leukocyte adherence inhibition: a simple test for cell-mediated tumor immunity and serum blocking factors. Int J Cancer. 1972;9:477. doi: 10.1002/ijc.2910090304. [DOI] [PubMed] [Google Scholar]
  • 6.Halliday WJ, Webb M. Delayed hypersensitivity to chemically induced tumors in mice and correlation with an in vitro test. J Natl Cancer Inst. 1969;43:141. [PubMed] [Google Scholar]
  • 7.Hauptfeld V, Kapp JA, Frederick K, Trial J, Shreffler DC. Monoclonal antibodies to mouse antigens: II. Characterization of thirty-one anti-I-J reagents. Immunogenetics. 1985;21:193. doi: 10.1007/BF00364872. [DOI] [PubMed] [Google Scholar]
  • 8.Hellström I, Hellström KE. Studies on cellular immunity and its serum-mediated inhibition in Moloney-virus induced mouse sarcoma. Int J Cancer. 1969;4:587. doi: 10.1002/ijc.2910040503. [DOI] [PubMed] [Google Scholar]
  • 9.Herlyn D, Wettendorf M, Schmoll E, Iliopoulos D, Schedel I, Dreikhausen U, Raab R, Ross AH, Jaksche H, Scriba M, Koprowski H. Anti-idiotype immunization of cancer patients: modulation of the immune response. Proc Natl Acad Sci USA. 1987;84:8055. doi: 10.1073/pnas.84.22.8055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Koppi TA, Halliday WJ. Further characterization of the cells involved in leukocyte adherence inhibition with murine tumor extracts. Cell Immunol. 1981;66:394. doi: 10.1016/0008-8749(82)90189-7. [DOI] [PubMed] [Google Scholar]
  • 11.Koppi TA, Halliday WJ. Cellular origin of blocking factors from cultured spleen cells of tumour bearing mice. Cell Immunol. 1983;76:29. doi: 10.1016/0008-8749(83)90345-3. [DOI] [PubMed] [Google Scholar]
  • 12.Koppi TA, Halliday WJ, McKenzie IFC. Regulation of cell mediated immunologic reactivity to Moloney murine sarcoma virusinduced tumours: II. Nature of blocking and unblocking factors in serum. J Natl Cancer Inst. 1981;66:1097. doi: 10.1093/jnci/66.6.1097. [DOI] [PubMed] [Google Scholar]
  • 13.Koppi-Reynolds TA, Halliday WJ. A two-chain tumour-related suppressor factor specific for a sequenced antigen. Immunol Lett. 1984;8:219. doi: 10.1016/0165-2478(84)90082-8. [DOI] [PubMed] [Google Scholar]
  • 14.Kuchroo VK, Lee VK, Hellström I, Hellström KE, Halliday WJ. Tumor-specific idiotopes on suppressor factors and suppressor cells revealed by monoclonal anti-idiotope antibodies. Cell Immunol. 1986;104:105. doi: 10.1016/0008-8749(87)90011-6. [DOI] [PubMed] [Google Scholar]
  • 15.Lee VK, Harriott TG, Kuchroo VK, Halliday WJ, Hellström I, Hellström KE. Monoclonal anti-idiotypic antibodies related to a murine oncofetal bladder tumor antigen induce specific cell-mediated tumor immunity. Proc Natl Acad Sci USA. 1985;82:6286. doi: 10.1073/pnas.82.18.6286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Maier T, Tench Stammers A, Levy JG. Characterization of a monoclonal antibody directed to a T cell suppressor factor. J Immunol. 1983;131:1843. [PubMed] [Google Scholar]
  • 17.Monroe JG, Gurish M, Dambrauskas J, Slaoui M, Lowy A, Greene MI. Genetic and biological characterization of a T-suppressor cell induced by anti-idiotypic antibody. J Immunol. 1985;135:1589. [PubMed] [Google Scholar]
  • 18.Nelson K, Cory J, Hellström I, Hellström KE. T-T hybridoma product specifically suppresses tumor immunity. Proc Natl Acad Sci USA. 1980;77:2866. doi: 10.1073/pnas.77.5.2866. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Nelson K, Pollack SB, Hellström KE. Specific anti-tumor responses of cultured immune spleen cells: III. Further characterization of cells which synthesize factors with blocking and antiserum dependent cellular cytotoxic (ADC) activities. Int J Cancer. 1975;16:539. doi: 10.1002/ijc.2910160404. [DOI] [PubMed] [Google Scholar]
  • 20.Nelson KA, George E, Swenson C, Forstrom JW, Hellström KE. Immunotherapy of murine sarcomas with auto-anti-idiotypic monoclonal antibodies which bind to tumor-specific T cells. J Immunol. 1987;139:2110. [PubMed] [Google Scholar]
  • 21.Rajewski K, Takemori T. Genetics, expression and function of idiotypes. Annu Rev Immunol. 1983;1:569. doi: 10.1146/annurev.iy.01.040183.003033. [DOI] [PubMed] [Google Scholar]
  • 22.Steele JK, Chan A, Stammers AT, Singhai R, Levy JG. Immune regulation in neoplasia. Dominance of suppressor systems. In: Greene MI, Hamaoka T, editors. Development and recognition of the transformed cell. New York: Plenum; 1987. p. 279. [Google Scholar]
  • 23.Steele JK, Lui D, Tench Stammers A, Whitney S, Levy JG. Suppression deletion therapy: selective elimination of T suppressor cells in vivo using a hematoporphyrin conjugated monoclonal antibody permits animals to reject syngeneic tumor cells. Cancer Immunol Immunother. 1988;26:125. doi: 10.1007/BF00205605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Steele JK, Kuchroo VK, Kawasaki H, Jayaraman S, Iwata M, Ishizaka K, Dorf ME. A monoclonal antibody raised to lipomodulin recognizes T suppressor factors in two independent haptenspecific suppressor networks. J Immunol. 1989;142:2213. [PubMed] [Google Scholar]
  • 25.Sy M-S, Bach BA, Dohi Y, Nisonoff A, Benacerraf B, Greene MI. Antigen- and receptor-driven regulatory mechanisms: I. Induction of suppressor T cells with anti-idiotypic antibodies. J Exp Med. 1979;150:1216. doi: 10.1084/jem.150.5.1216. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES